[TS-d as an adjuvant for cancer radiotherapy].
TS-d is a rough polysaccharide obtained from polyporaceae JB-2, 615, Kunming mice and rabbit and S180, MA737 tumors were used to study the effects of TS-d. Preliminary results indicated that TS-d is an effective radioprotective and antineoplastic drug with low toxicity and few side effects. When TS-d was injected i.p. to mice at a dosage of 400 mg/kg 60 min before 8.5Gy gamma-irradiation, the survival rate of mice was increased by 43% (P < 0.05) as compared with control. When 400 mg/kg of TS-d was injected i.p. into mice 60 min before 7.0 Gy gamma-irradiation, the number of WBC, BMC, and CFU-S were significantly increased (P < 0.01-0.001) as compared with control. The inhibitory rates of TS-d on S180 and MA737 were 46%-77% (P < 0.05 and P < 0.001) and 37%-46% (P < 0.05 and P < 0.05), respectively. TS-d showed significant protective effects on the hematopoietic tissues of rabbits exposed to-gamma-irradiation. The LD50(7d) values of TS-d given i.p. in Kunming mice were 4027.6 +/- 434.9 in male and 5115.6 +/- 453.5 mg/kg in female, and the LD50(7d) values of TS-d given i.v. in JB-2 mice were 1389.6 +/- 240.8 and 1361.5 +/- 208.3 mg/kg, respectively. TS-d had no effect on the growth of mice at the age of four weeks. TS-d had no effect on the production rate of micronucleus.
Li
S
S
Institute of Radiation Medicine, CAMS and PUMC, Tianjin.
D000818:Animals; D017024:Chemotherapy, Adjuvant; D005260:Female; D006413:Hematopoietic System / Q000187:drug effects / Q000528:radiation effects; D006801:Humans; D007928:Lethal Dose 50; D007970:Leukopenia / Q000188:drug therapy; D008297:Male; D051379:Mice; D015162:Micronucleus Tests; D009374:Neoplasms, Experimental / Q000188:drug therapy; D011124:Polyporaceae; D011134:Polysaccharides / Q000627:therapeutic use* / Q000633:toxicity; D011817:Rabbits; D011837:Radiation-Protective Agents / Q000627:therapeutic use* / Q000633:toxicity; D012510:Sarcoma 180 / Q000188:drug therapy
D011134:Polysaccharides; D011837:Radiation-Protective Agents